Omar Khwaja - 21 May 2021 Form 4 Insider Report for Voyager Therapeutics, Inc. (VYGR)

SEC form
4
Accepted by SEC
25 May 2021, 16:31:13 UTC
Next SEC filing
12 Nov 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Omar Khwaja filed Form 4 for Voyager Therapeutics, Inc. (VYGR) on 25 May 2021.

Key facts

  • This page summarizes Omar Khwaja's Form 4 filing for Voyager Therapeutics, Inc. (VYGR).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 25 May 2021, 16:31.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: -$14,169.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VYGR transaction

Common Stock

Sale

Transaction value
-$14,169
Shares
-3,516
Change %
-2.8%
Price
$4.03
Shares after
120,509
Date
21 May 2021
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on May 20, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

SEC remarks

Chief Medical Officer and Head of Research & Development.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .